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MEKANISME MOLEKUL RANSANGAN FASA AKUT:  
PENGENALPASTIAN LALU ISYARAT TRANSDUKSI YANG MEMBATAS 
KESAN PERENCATAN SITOKINA TERHADAP RESEPTOR AKTIVASI 
PEMBIAKAN PEROKSISOM ALPHA (PPARα)  
MANUSIA DALAM SEL HATI 
 
ABSTRAK 
 
 Sitokina seperti IL-6 memainkan peranan penting dalam merangsang 
tindakbalas fasa akut (APR) dalam badan semasa kecederaan dan inflamasi. Dinamik 
ekspresi dan interaksi oleh komponen laluan isyarat dalam pengawalaturan pembiakan 
peroksisom alpha (PPARα) semasa APR masih belum dikenalpasti. Dalam kajian ini, 
kita telah mengenalpasti tiga potensi laluan isyarat, JAK-STAT, PI3K dan MAPK (p38 
dan ERK1/2) yang berasas daripada komponen JAK dan SHP2 di bahagian hulu laluan 
IL-6, terlibat dalam merangsang perencatan pengekspresan gen PPARα. Penggunaan 
perencat-perencat spesifik terhadap laluan isyarat transduksi JAK, PI3K dan MAPK 
menunjukkan IL-6 merencat paras mRNA PPARα, melalui ransangan pengikatan 
STAT1 dan STAT3 ke elemen STAT pada promoter PPARα. Tambahan lagi, ekspresi 
lampau STAT1 dan STAT3 di dalam sel hati merencat aktiviti promoter PPARα, 
menunjukkan bahawa peningkatan dalam pengikatan aktiviti DNA dengan STAT 
merencatkan pengekspresan gen PPARα. Di samping itu, didapati bahawa rawatan 
dengan perencat-perencat specifik AG490, Rapamycin, SB203580 dan U0126 merencat 
kesan IL-6 dalam pengikatan aktiviti DNA STAT1 dan STAT3, menyarankan laluan 
simpang antara laluan-lalaun isyarat tersebut. Sebagai rumusan, di dalam kehadiran 
perencat-perencat spesifik, kesan IL-6 ke atas pengekspresan protein dan aktiviti 
pengikatan DNA dengan STAT1 dan STAT3 direncat secara keseluruhan atau 
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sebahagian. Secara keseluruhannya, kajian ini telah berjaya menemukan laluan baru 
yang merangsangkan perencatan pengekspresan gen PPARα oleh IL-6 yang melibatkan 
modulasi laluan JAK-STAT, JAK-PI3K-Akt-mTOR-STAT dan SHP-MAPK (p38-
STAT dan ERK1/2-STAT). Kajian ini juga menumpukan perhatian signifikan terhadap 
JAK-STAT sebagai laluan dominan disebabkan laluan simpang di antara JAK-STAT 
dengan PI3K, dan, MAPK melalui aktivasi SHP, dan, transkripsi aktivator STAT di 
dalam pengawalaturan pengekspresan PPARα mRNA. Oleh itu, penentuan laluan yang 
mengawalatur pengekspresan PPARα di dalam sel hati yang dirawat oleh IL-6 
mencadangkan keupayaan peranan fisiologi oleh PPARα memodulasi APR dan 
berkeupayaan mempunyai implikasi terapeutik di dalam pembentukan APR.  
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MOLECULAR MECHANISM OF ACUTE PHASE RESPONSE: 
IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS MEDIATING 
CYTOKINE-INHIBITORY EFFECT ON HUMAN PEROXISOME 
PROLIFERATOR ACTIVATED RECEPTOR ALPHA  
(PPARα) IN LIVER CELLS 
 
ABSTRACT 
 
Cytokines, like IL-6, play an important role in triggering the acute phase 
response (APR) of the body to injury and inflammation. The dynamics of expression 
and interaction of the IL-6 signalling pathway components in the regulation of 
peroxisome proliferator-activated receptor alpha (PPARα) during APR remain to be 
properly identified. In this study, we determined that three possible potential signaling 
pathways, JAK-STAT, PI3K and MAPK (p38 and ERK1/2) which derived from the 
upstream JAK and SHP2 components of the IL-6 signalling were involved in              
IL-6-inhibitory effect on PPARα gene expression. Pre-treatment of cells with the 
pharmacological inhibitors of JAK2, PI3K and MAPK, demonstrated that IL-6 inhibited 
the mRNA levels of PPARα via activating the binding of STAT1 and STAT3 to STAT 
binding site in the PPARα promoter. Moreover, over expression of the STAT1 and 
STAT3 in the liver cells decreased PPARα promoter activity, indicating that an increase 
in DNA binding activity of STAT1 and STAT3 inhibited the PPARα gene expression. 
It was also found that AG490, Rapamycin, SB203580 and U0126 inhibitors attenuated 
the action of IL-6 on the DNA binding of STAT1 and STAT3, suggesting a cross-talk 
between the signaling pathways. In short, in the presence of all the inhibitors, the effect 
of IL-6 on protein expression and DNA binding of STAT1 and STAT3 were either 
completely or partially inhibited. Taken together, this study has successfully unraveled 
 xxix 
novel pathways by which IL-6 inhibited PPARα gene transcription, involving the 
modulation of JAK-STAT, JAK-associated PI3K-Akt-mTOR-STAT and SHP-mediated 
MAPK (p38-STAT and ERK1/2-STAT) pathways. The present study also underlines 
the significance of JAK-STAT as a dominant pathway due to cross-talks between JAK-
STAT with PI3K, and, MAPK pathways via SHP activation, and, STAT transcription 
factors in down regulating the PPARα mRNA expression. Thus, the determination of 
the regulatory pathways of PPARα in IL-6-treated liver cells strongly suggests the 
potential physiological role for PPARα in modulating APR and may have immediate 
therapeutic implications in the development of APR. 
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INTRODUCTION 
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1.1 Historical Background 
 The concept of peroxisome proliferation was first initiated when Hess and his 
colleagues discovered that the administration of hypolipidemic drug resulted in 
enlarged liver or hepatomagaly which was caused by an increase in the number and 
size of intracellular peroxisomes (Hess et al., 1965). Subsequently, a group of 
structurally diverse agents was found to promote and increase the number of hepatic 
peroxisome in rodents. Therefore, these agents are collectively named “peroxisome 
proliferators” (Reddy and Krishnakantha, 1975).   
 By 1980, Reddy and co-workers discovered that chronic, long-term 
administration of these chemicals to rats also resulted in liver cancer (Reddy et al., 
1980). These classic observations laid a foundation for the focus of future research to 
elucidate the mechanisms underlying the effect of peroxisome proliferators. The 
discovery of nuclear receptors aided this pursuit and it was soon hypothesized that the 
effects induced by peroxisome proliferators were the result of a receptor-mediated 
mechanism (Reddy and Lalwai, 1983). However, it was not until 1990 that a receptor 
was cloned and shown to be activated by this class of chemicals (Issemann and Green, 
1990) and thus termed the peroxisome proliferator-activated receptor (PPAR).  
 A family of transcription factors, known as PPARs which consists of PPARα, 
PPARβ/δ, PPARγ, has moved from the status of orphan receptor to one of the best 
characterised nuclear receptors. Their functional characterisation provides unique 
insights into the role of fat in health and diseases. Recently, this nuclear receptor has 
also been shown to fulfil critical unique roles in general transcriptional control of 
numerous cellular processes, with implications in inflammation, atherosclerosis, 
cancer development and epidermal wound healing (Pineda-Torra et al., 2002). 
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1.2 Peroxisome proliferator-activated receptors (PPARs) 
 PPARs are members of nuclear hormone receptor (NHR) superfamily, the 
largest family of transcription factors. There are three distinct PPAR subtypes; 
PPARα (also referred to as NR1C1), PPARβ/ (NR1C2) and PPAR (NR1C3), each 
encoded by separate genes and with specific tissue distribution pattern and metabolic 
functions (Issemann and Green, 1990, Dreyer et al., 1992, Kliewer et al., 1994, 
Braissant et al., 1996, Pineda-Torra et al., 2007).  
All three PPAR isoforms possess similar structural and functional features. 
Principally, four functional domains have been identified which are called A/B, C, D 
and E/F (Figure 1.1). The N-terminal A/B domain contains a ligand-independent 
activation function 1 (AF-1) (Werman et al., 1997) responsible for the 
phosphorylation of PPAR. The DNA binding domain (DBD) or C domain promotes 
the binding of PPAR to the peroxisome proliferator response element (PPRE) in the 
promoter region of target genes (Kliewer et al., 1992). The D site is a docking domain 
for cofactors. The E/F domain or ligand-binding domain (LBD) is responsible for 
ligand specificity and activation of PPAR binding to the PPRE, which increases the 
expression of the target genes.  
Prior to transcriptional activation, PPAR heterodimerises with RXR to form a 
complex (Kliewer et al., 1992). RXRs are also members of the NHR superfamily that 
are activated following binding with 9 cis-RA (9-cis retinoic acid) (Desvergne and 
Wahli, 1999). PPAR/RXR heterodimer recognises sequences situated within the DR1 
motif, whereby PPAR interacts with the upstream extended core hexamer of the DR1, 
whereas RXR occupies the downstream motif (Palmer et al., 1995; Ijpenberg et al., 
1997).  
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Figure 1.1 Schematic representation of the structural domains of PPAR. 
PPAR consists of four distinct functional domains. The A/B domain is located at the 
N-terminal with AF-1 is responsible for phosphorylation, the domain C is implicated 
in DNA binding, domain D is the docking region for cofactors and domain E/F is the 
ligand binding domain, containing AF-2, which promotes the recruitment of cofactors 
required for gene transcription. AF-1, activating function-1; DBD, DNA binding 
domain; AF-2, activating function-2; LBD, ligand-binding domain; RXR, retinoid-X-
receptor; PPRE, peroxisome proliferators response element. 
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1.3 Peroxisome proliferator-activated receptor α (PPARα) 
 PPARα was the first PPAR to be identified (Issemann and Green, 1990). 
PPARα was isolated by screening a mouse liver cDNA library using a probe based on 
the consensus sequence of the DNA binding domain of several nuclear receptors. 
Full-length PPARα cDNA was found to encode a 468 amino acid protein with 
predicted molecular weight of 52 kDa. Analysis of the amino acid sequence 
demonstrated that PPARα belonged to the steroid hormone receptor superfamily since 
it had all the typical characteristics of steroid receptor (Evans et al., 1988). The 
PPARα amino acid sequence displayed high homology to the DNA binding region of 
nuclear steroid hormone receptors such as the glucocorticoid receptor, estrogen 
receptor, retinoid X receptor, vitamin D receptor, thyroid receptor and retinoic acid 
receptor.  
PPARα was also cloned from frog, rat, guinea pig and human (Wilson et al., 
2002). In humans and rodents, high level of PPARα mRNA is found in liver, heart, 
kidney and muscle. However, the mRNA level of PPARα in human liver appears 
lower than in rodent liver (Palmer et al., 2002). In addition, it is expressed in 
steroidogenic tissue such as adrenals (Hierlihy et al., 2006). Furthermore, human 
PPARα is also expressed in vascular cells including endothelial cells (Inoue et al., 
2001), smooth muscle cells (Staels et al., 1998a; Diep et al., 2006) and 
monocytes/macrophages (Staels et al., 1998a; Chinetti et al., 1998; Neve et al., 2003).  
In mouse and rat, PPARα appears late in the development (Braissant and 
Wahli, 1998; Desvergne and Wahli, 1999). In adult rat, relatively high levels of 
PPARα mRNA are detected in brown fat, liver, kidney, heart and the mucosa of 
stomach and duodenum. In addition, significant amounts of PPARα mRNA are also 
expressed in the retina, adrenal gland, skeletal muscle and pancreatic islets (Braissant 
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and Wahli, 1998). Therefore, it plays an important role in the regulation of 
intermediary metabolism, which has been very well studied in liver. Regardless of 
species, the expression of PPARα correlates with high mitochondrial and peroxisomal 
-oxidation activities.  
 
1.4 Ligands of PPARα 
 PPARα is a ligand-activated transcription factor. The binding of ligands to the 
receptor greatly increases its transcriptional activity. A diverse range of compounds 
which include natural (endogenous) and synthetic (exogenous) substances serve as 
PPARα ligands, including fatty acids and fatty acid-derived products as well as 
pharmacological molecules such as plasticizers and herbicides (Isseman and Green, 
1990; Forman et al., 1997; Krey et al., 1997; Ward et al., 1998; Lin et al., 1999; Kota 
et al., 2005) (Table 1.1). The ability of PPARα to bind multiple natural and synthetic 
ligands is due to the structure of the ligand binding domain of PPARα. The ligand 
binding domain is made out of a three-dimensional fold, which consists of an 
antiparallel α-helical sandwich of 12 helixes (Helix 1 to Helix 12) organised in three 
layers with a central ligand binding hydrophobic pocket (Bourguet et al., 1995; Xu et 
al., 2001; Wahli, 2002). Upon ligand binding, the ligand binding pocket closes and 
forms a ‘mouse trap model’ (Wahli, 2002). Xu et al. (2006) identified the major 
determinant of selectivity of ligands in PPARα is the amino acid residue Tyr-314. 
This amino acid plays an important part in the transcriptional activation of PPARα 
receptor by ligands. 
 
 
 7 
Table 1.1  The PPARα natural (endogenous) and synthetic (exogenous) 
ligands. PPARα can be activated by a structurally diverse group of ligands, which 
bind to PPARα and increase the transcriptional activity. 
 
Natural (Endogenous) Ligands Synthetic (Exogenous) Ligands 
Palmitic acid 
Stearic acid 
Oleic acid 
Linoleic acid 
Arachhidonic acid 
Eicosapentaenoic acid 
Leukotriene B4 
Wy-14, 643 
Clofibrate 
Gemfibrozil 
Nafenopin 
Bezafibrate 
Fenofibrate 
Fenoprofen 
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 A range of saturated and unsaturated fatty acids could activate PPARα 
(Gottlicher et al., 1992; Burkart et al., 2007). Palimitic acid, oleic acid, linoleic acid 
and arachidonic acid are examples of saturated acid that can activate PPARα (Banner 
et al., 2007). Notably, PPARα is the only PPAR subtype that binds with high affinity 
to a wide range of saturated acids. This may be because the PPARα pocket is more 
lipophilic and less solvent compared to the other PPAR subtypes, explaining its 
selectivity for more lipophilic saturated fatty acids (Xu et al., 2005). The most notable 
synthetic PPARα ligand is the hypolipidemic fibrates drugs. Wy-14643, clofibric acid, 
ciprofibrate, fenofibrate and gemfibrozil are examples of fibrates that can activate 
PPARα. Clofibric acid and fenofibric acid are dual activators of PPARα and PPARγ, 
with 10-fold selectivity for PPARα (Isseman and Green, 1990). 
 
1.5 Structural organisation of PPARα 
 The human PPARα has been mapped to chromosome 22q12-q13.1 by somatic 
cell hybridisation and linkage analysis (Sher et al., 1993). The human PPARα gene is 
composed of twelve exons which spanned approximately 85kb, with 5’-untranslated 
region coded by exons A, 1a, 2a, 2b and part of exon 3 (Vohl et al., 2000; Chew et al., 
2003). The coding region of PPAR comprises the remainder of exon 3 and exon 4-8, 
with the 3’-untranslated region consisting of the last 232 bp of exon 8. The introns 
length vary between 0.6 kb to 20 kb as indicated in Figure 1.2. 
 Recently, four promoters (A, B, C, D) which are responsible in transcribing 
six alternatively spliced variants in the 5’-untranslated region (UTR) of human 
PPARα were identified (Chew et al., 2003) (Figure 1.2). Promoters A and B are 
responsible in transcribing two variants each, while promoters C and D transcribe one 
variant each (Chew et al., 2003; Chew et al., 2007). 
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Figure 1.2 Schematic representation of the structural organisation of human 
PPARα gene. The gene spans 85 kb of genomic DNA. The spatial localisation of 
exons within the gene and the size of introns are indicated in the upper and lower 
panel respectively. Untranslated region    coding regions    are also indicated. Block 
arrows indicate the location of the four promoters A, B, C and D.  
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1.6 Physiological roles of PPARα 
1.6.1 PPARα and fatty metabolism 
 PPARα serves a fundamental role in mammals by acting as a central 
modulator of signalling molecules that mediate changes in gene expression to 
maintain lipid homeostasis. PPARα is highly expressed in tissues with elevated rates 
of fatty acid catabolism, whereby through the interaction with PPRE on the promoter 
region of several genes, PPARα and its ligands regulate the transcription of the genes 
of key enzymes and proteins such as fatty acid transport protein (FATP), fatty acid 
translocase (FAT/CD36) and Acyl-CoA synthetase (ACS) that play crucial roles in 
the lipid and fatty acid metabolism (Schoonjans et al., 1996a; Chinetti et al., 2001; Ye 
et al., 2001; van Raalte et al., 2004; Israelian-Konaraki and Reaven, 2005). 
 Intracellular fatty acid concentrations are partly regulated by import and 
export system that is controlled by FATP, FAT/CD36 and ACS. These proteins 
facilitate the transport of fatty acids through the cell membrane and their esterification 
preventing their efflux (Abumrad et al., 1993, Schoonjans et al,, 1995, Martin et al., 
1997, Tontonoz and Mangelsdorf, 2001). 
 PPARα acts as a regulator of intracellular fatty acid uptake controls. 
Treatment with PPARα agonists (activators) has been shown to induce FATP mRNA 
levels in rat liver and intestine, and induce ACS mRNA levels in liver and kidney 
(Schoonjans et al., 1995, Martin et al., 1997, Motojima et al., 1998, Fruchart et al., 
2004). Recent experiments carried out using LDL receptor-deficient mice also 
showed similar induction in ACS mRNA (Srivasta et al., 2006). These evidence show 
that PPARα activators influence fatty acid cellular uptake, which is a crucial 
regulatory step in lipid metabolism. 
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 Once inside the cells, fatty acid must penetrate into the mitochondria where its 
metabolism takes place. Muscle-type carnitine palmitoyl transferase type I (CPT-I), a 
key enzyme in mitochondrial fatty acid catabolism, contains a PPRE in its promoter 
region and is regulated by PPARα activators (Brandt et al., 1998, Mascaro et al., 
1998, Chinetti et al., 2001, Louet et al., 2001). Furthermore, activation of PPARα was 
proven to up-regulate the gene expression of mitochondrial 3-hydroxy-3-
methyglutaryl-CoA (HMG-CoA) synthase (Rodriguez et al., 1994, Meertens et al., 
2005). HMG-CoA synthase is a key enzyme in ketogenesis. HMG-CoA catalyses the 
condensation of acetyl-CoA and generates HMG-CoA, which is eventually converted 
into ketone bodies (Rodriguez et al., 1994, Meerten et al., 2005). These observations, 
taken together, indicate that PPARα controls fatty acid uptake, activation into        
acyl-CoA esters and degradation through the peroxisomal and mitochondrial β-
oxidation pathways, and the synthesis of ketones (Chinetti et al., 2001).  
 
1.6.2 PPARα and triglyceride-rich lipoprotein metabolism 
There is increasing evidence that serum triglycerides are strong risk factors in 
cardiovascular disease. One of the major effects of PPARα activation on lipid 
metabolism is to reduce triglyceride-rich levels in plasma. PPARα activators alter the 
synthesis and the catabolism of the trigyceride-rich lipoproteins in a way that 
decreases plasma triglyceride levels via induction of the lipoprotein lipase (LPL) 
activity (Schoonjans et al., 1996b). 
 Schoonjans et al. (1996b) demonstrated that PPARα mediates the triglyceride-
lowering action of PPARα activators by increasing lipoprotein lipase gene expression 
in PPRE-mediated manner. PPRE was found to be present in the human lipoprotein 
lipase promoter which was responsible in stimulating the expression of the gene. Two 
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distinct mechanisms may be involved in PPARα induction of lipoprotein lipase 
activity: firstly, through the stimulation of the LPL gene expression and secondly, by 
the induction of hydrolytic activity of enzyme for triglyceride-rich lipoproteins 
secreted following treatment with PPARα activators (Fruchart et al., 1999). 
 Research carried out by Srivastava et al. (2006) further supported the above-
mentioned mechanisms. A PPARα ligand, fenofibrate, was demonstrated to improve 
lipid abnormalities, such as lowering serum triglycerides and cholesterol, improving 
insulin sensitivity, and preventing accumulation of lipids in the aorta. In addition, this 
research showed that fenofibrate mediated its effect partly via inhibition of 
triglyceride production and partly via clearance of triglyceride-rich apolipoprotein B 
(Apo B) particles by elevating LPL and reducing apolipoprotein CIII (Apo CIII). 
Apo CIII plays a key role in delaying the catabolim of triglyceride rich 
particles, by inhibiting their binding to the endothelial surface and lipolysis by LPL 
(Hertz et al., 1995, Staels et al., 1995, Desvergne and Wahli, 1999, Vosper et al., 
2007). PPARα activators were also proven to decrease Apo CIII levels, thus resulting 
in an enhanced lipolytic activity (Hertz et al., 1995, Staels et al., 1995). A few 
mechanisms may be involved in this negative regulation. Firstly, PPARα activators 
might supress Apo CIII by displacing the strong transcriptional activator of the 
apolipoprotein gene with a lesser active complex, resulting in lower Apo CIII 
promoter activity (Hertz et al., 1995). Secondly, there is a possibility that PPARα 
activators indirectly decrease the expression of a strong transcriptional activator of the 
Apo CIII gene, i.e. the hepatocytes nuclear factor-4 (HNF-4) (Hertz et al., 1995). 
Alternatively, PPARα activators may induce the expression of repressor proteins of 
the Apo CIII gene, such as apolipoprotein A-I regulatory protein-1, Ear3/COUP-TF or 
Rev-erb-alpha (Vu-Dac et al., 1998, van Raalte et al., 2004, Becker et al., 2006).  
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1.6.3 PPARα in inflammation, atherosclerosis and thrombosis 
 Atherosclerosis is a long term process which involves recruitment and 
activation of different cell types, leading to inflammatory response. It is a 
multifactorial disease in which the occurrence of lesions may result in ischemia of the 
heart, brain, resulting in infarction (Zaman et al., 2000).  
 Specifically, the process of formation of atherosclerotic plaque involves 
recruitment of circulating monocytes, which must first adhere to the endothelium 
before their invasion into vessel intima, where they subsequently develop into tissue 
macrophages. These macrophages accumulate intracellular lipid to become foam cells 
which in turn, produce cytokines and other pro-inflammatory signals, which further 
stimulate monocyte recruitment to the plaque. These signals also induce vascular 
smooth cell proliferation and invasion. Developments in the plaque will induce 
apoptosis of cells in the centre as well as possible plaque destabilization and rupture 
with subsequent thrombus formation (Vosper et al., 2002). PPARα has been widely 
shown to play an important role in the development of atherosclerosis (Zanbergen and 
Plutzky, 2007; Izzo et al., 2009). PPARα is abundantly present in the atherosclerotic 
lesions and in primary cultures of endothelial cells, smooth muscle cells and 
macrophage foam cells (Chinetti et al., 1998; Staels et al., 1998a). In addition, 
PPARα is present in isolated human monocyte and its expression increases upon 
differentiation into macrophages (Chinetti et al., 1998). Clinical studies performed 
showed that PPARα activators (fibrates) lower the progression of atherosclerosis in 
both human and animals (Hahmann et al., 1991; Fruchart et al., 1999; Fruchart, 2001; 
Fruchart, 2009).  
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 Adhesion of circulating monocytes is a critical early step in atherogenesis. 
Marx et al. (1999) reported that PPARα inhibits cytokine-induced (TNF-α) vascular 
cell adhesion molecule-1 (VCAM-1), an adhesion molecule critical for monocytes 
recruitment to atherosclerotic lesions (Marx et al., 1999; Chinetti et al., 2001). This 
strongly suggests that PPARα may reduce the recruitment and adherance of monocyte 
to the endothelium. In addition, PPARα also reduces VCAM-1 expression in 
endothelial cells (Chinetti et al., 1998; Neve et al., 2000). 
 In human vascular endothelial cells, PPARα activation represses thrombin-
induced expression of endothelin-1 (ET-1), a potent vasoconstrictor peptide and 
inducer of smooth muscle cell proliferation (Delerive et al., 1999b). PPARα activators 
repress the ET-1 production by interfering with AP-1 signalling pathway, which 
mediates thrombin activation of endothelin-1 gene transcription (Delerive et al., 
1999b) (Figure 1.3).  
 PPARα has also been implicated to interfere with transcription of several 
inflammatory response genes. For example, PPARα activators inhibit the expression 
of inducible cyclo-oxygenase-2 (COX-2) through negative interference with NFκB 
activation (Staels et al., 1998a; Meade et al., 1999). COX-2 is a catalyser of the 
production of prostanoids, which are major effectors of inflammation response (Paik 
et al., 2000). In human aortic smooth muscle cells, PPARα activators inhibit 
interleukin-1 (IL-1)-induced secretion of interleukin-6 (IL-6) and keto prostaglandin 
F1-alpha (6-keto-PGF1-alpha). IL-6 controls macrophages and T-cell activation, as well 
as vascular smooth muscle cell proliferation and migration. It also plays a major 
regulatory role in the acute phase response and is considered an accurate marker of 
vascular inflammation. IL-6 also induces the potent monocyte chemoattractant 
protein-1 (MCP-1) in peripheral blood mononuclear cells, which the inhibition of IL-6 
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Figure 1.3 Peroxisome proliferator-activated receptor alpha activators inhibit 
vascular inflammation, induce apoptosis and decrease endothelin-1 secretion by 
endothelial cells. NFB, Nuclear factor -B; AP-1, activated protein-1;  IFN-, 
interferon-gamma; IKK, IB kinase; IL, interleukin; COX, cyclooxygenase; iNOS, 
inducible nitric oxide synthase; TNF, tumour necrosis factor alpha; EC, vascular 
endothelial cells; SMC, vascular smooth muscle cells; M, macrophages. 
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will slow down recruitment of monocytes to developing plaques. PPARα activators 
repress the expression of both IL-6 and 6-keto-PGF1-alpha through negative cross-talk 
of activated PPARα with transcriptional factors NFκB and AP-1 signalling pathways 
(Staels et al., 1998a; Delerive et al., 1999a; Delerive et al., 2001). 
 Recently, Neve et al. (2001) demonstrated that PPARα agonists inhibit tissue 
factor (TF) expression in human monocytes and macrophages (Neve et al., 2001). 
Monocytic TF expression contributes to trombogenicity associated with plaque 
rapture and may propagate thrombus formation at the site of vascular lesions. In 
addition, TF also mediates adhesion and migration of monocytes (Neve et al., 2001). 
In addition, synthetic PPARα agonist WY-14643 has been shown to reduce inducible 
nitric oxide synthase (iNOS) which is key inflammatory enzyme in macrophages. The 
inhibition by PPARα is suggested to be mediated through the modulation of the stress 
protein, heme oxygenase 1 (Colville-Nash et al., 1998; Fruchart et al., 1999). 
 Scavenger receptor A (SR-A) is significant in the generation of atherosclerosis 
plaque. It mediates the uptake of modified low-density lipoprotein (LDL) which plays 
key role in the formation of the foam cell (Vosper et al., 2002). Matrix 
metalloproteinase (MMP)-9 (gelatinase B) is produced by macrophages to degrade 
collagen IV in the basement membrane, facilitating invasion through the vessel wall 
and into the intima. PPARα agonists are capable of blocking expression of both SR-A 
and MMP-9, and thus act in an anti-inflammatory and atherosclerotic manner 
(Fruchart et al., 1999; Vosper et al., 2002). 
 Finally, there is evidence that PPARα agonists are able to reduce levels of 
plasma pro-coagulant factors fibrinogen in human, which is an acute-phase protein 
whose expression is up-regulated by cytokines during inflammation (Staels et al., 
1998a). This, in turn, reduces the likelihood of thrombogenesis (Staels et al., 1998a; 
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Kockx et al., 1999; Vosper et al., 2002). IL-6 is known to up-regulate fibrinogen 
expression, and it may be through the negative effects of PPARα agonists on IL-6 
expression that reduces the fibrinogen levels (Castell et al., 1989). 
 In addition, PPARα agonists also significantly decrease plasma levels of 
cytokines and acute phase proteins such as C-reactive protein (CRP), which are 
established risk factors for cardiovascular disease. Thus, these data taken together 
indicate that PPARα activators exert anti-inflammatory activities in humans (Staels et 
al., 1998b; Chinetti et al., 2001). 
 Therefore, PPARα plays a novel role in atherosclerosis. PPARα may interfere 
with proatherogenic processes at different levels. Firstly, PPARα exerts beneficial 
effects on atherosclerosis by changing plasma lipid and lipoprotein profiles toward 
less atherogenic levels. Secondly, PPARα interferes with the development of 
atherosclerosis by inhibiting inflammatory response at the level of vascular wall. 
PPARα may interfere with the early stages of atherosclerotic lesion development by 
affecting monocyte recruitment by inhibiting TNF-α-induced VCAM-1 expression in 
endothelial cells. Furthermore, PPARα may also influence the later stages of 
atherosclerosis by inducing apoptosis of activated human macrophages. In Figure 1.4, 
the summary of the effects PPARα activation on vascular inflammation, 
atherosclerosis and thrombosis is shown (Chinetti et al., 2001; Fruchart, 2009). 
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Figure 1.4 PPARα controls vascular inflammation and thrombosis related to 
atherosclerosis. CAM, cellular adhesion molecule; ET-1, endothelin-1, IL, 
interleukin; MCP1, monocyte chemoattractant protein; MMP, metaloproteinase; PAI-
1, plasminogen activator inhibitor type 1; PG, prostaglandin, TF, tissue factor; TNF, 
tumour necrosis factor. 
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1.7 Acute phase response (APR) 
 The APR is a prominent systemic reaction of the organism to local or systemic 
disturbances in its homeostasis caused by infection, tissue injury, trauma and surgery, 
neoplastic growth or immunological disorders (Baumann and Gauldine, 1994; 
Moshage, 1997; Bengmark, 2004; Lowenstein and Matsushita, 2004; Gruys et al., 
2005). The APR is beneficial to the injured organism with the aim of restoring the 
disturbed physiological homeostasis (Moshage, 1997; Lowenstein and Matsushita, 
2004; Gruys et al., 2005). 
 There are three main components of APR, i.e. activators, regulators and 
effectors, as depicted in Figure 1.5. At the site of invasion by the microorganism and 
the place of tissue injury, a number of responses of the tissue itself are initiated. Pro-
inflammatory cytokines which would act as activators of APR are released, and the 
vascular system and inflammatory cells are activated. These responses in turn are 
associated with production of more cytokines and other inflammatory mediators, 
which diffuse to the extracellular fluid compartment, circulate in the blood and bind to 
receptors on endothelial cells and hepatocytes, thus amplifying a local response into a 
systemic inflammatory response. Activators of the APR initiate an intracellular signal 
transduction cascade that activates the three major transcription factors (STAT3, 
NFκB, C/EBPβ) which alone or in combination with other proteins regulate 
transcription of APR effector genes. For example, previous reports have suggested a 
role of STAT3 in regulation of haptoglobin in liver cells. The STATs are latent 
transcription factors that are activated by tyrosine phosphorylation. After 
phosphorylation, the STAT proteins homo- or heterodimerize and translocate to the 
nucleus to activate the transcription of many target genes, including APPs (Darnell, 
1997; Kurash et al., 2004). 
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Figure 1.5 Components of the acute phase response. Activated innate immune 
cells release activators of the APR (IL-6, TNF-α, IL-1). Activators interact with their 
respective receptors, inducing transcriptional regulators of the APR, including 
STAT3, NFκB and C/EBPβ. These transcriptional factors direct the synthesis of acute 
phase effector proteins, which mediate the APR. (Adapted from Lowenstain and 
Matsushita, 2004) 
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 The APR is accompanied by specific changes in the concentration of plasma 
proteins, which would act as effectors of the APR. Proteins that increased by at least 
25% during the APR are positive APP (e.g. CRP, serum amyloid A (SAA) and 
fibrinogen), whereas proteins that decreased are negative APPs (e.g. albumin, 
transferrin, and -fetoprotein). Changes in APP concentrations are largely attributable 
to alterations in their rate of synthesis in the liver (Morley and Kushner, 1982; Gabey 
and Kushner, 1999; Khovidhunkit et al., 2004). 
 In the liver, TNF-α, IL-1 and IL-6 play a key role in APR (Le and Vilcek, 
1989; Sehgal et al., 1989a; Heinrich et al., 1991). These cytokines activate 
hepatocytic secretion of most of the APP via activating hepatocytic receptors (Le and 
Vilcek, 1989; Sehgal et al., 1989a; Heinrich et al., 2003). IL-6 is the major mediator 
for the hepatocytic secretion of the most of the APP (Le and Vilcek, 1989; Sehgal et 
al., 1989b; Heinrich et al., 2003). Table 1.2 shows the major cytokines involved in 
APR, their cellular sources and biological functions. Furthermore, it has been shown 
that Kupper cells play an intermediate role. After stimulation by the pro-inflammatory 
cytokines, the Kupper cells release IL-6 and suppress mononuclear phagocytic 
production of IL-1 and TNF-α (Schindler et al., 1990; Gruys et al., 2005), thus 
mitigating the whole cascade reaction. Down-regulation of the hepatocytic APR is 
achieved by rapid hepatic removal of circulating cytokines (Heinrich et al., 1991; 
Heinrich et al., 2003). 
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Table 1.2 List of cytokines important in acute phase response, their most 
important cellular source and biological function 
 
Cytokine Cellular Source Biological Activity 
IL-1α 
IL-1β 
Monocyte 
Macrophages, B-cells 
and dendritic cells 
Promote inflammation; activate the coagulation 
pathway; stimulate the liver to produce APP; 
catabolism of fat for energy conversion; 
stimulate the synthesis of collagen and 
collagenase for scar tissue formation; stimulate 
the synthesis of adhesion factors on endothelial 
cells and leukocytes for diapedesis; and activate 
macrophages 
IL-6 Monocytes, 
macrophages, 
fibroblasts, Th2 cells, 
stromal cells and 
endothelial cells 
Stimulates the liver to produce APP; stimulates 
the proliferation of B-lymphocytes; antibody 
production and increases neutrophil production; 
induces myeloma and plasmacytoma growth; 
nerve cell differentiation. 
TNF-α Monocytes, 
macrophages, Th1 cells, 
dendritic cells and NK 
cells 
Works synergistically with IL-1 to enhance 
inflammation. Functions include acting on 
endothelial cells to stimulate inflammation and 
the coagulation pathway; stimulates 
macrophages to secrete IL-1 for redundancy; 
activates neutrophils and promoting 
extracellular killing by neutrophils; stimulates 
the liver to produce APP, and acts on muscles 
and fat to stimulate catabolism for energy 
conversion 
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1.7.1 PPARα and acute phase response 
 Several studies have shown that the expression levels of APP are regulated by 
fibrates, which act via PPARα dependent mechanisms (Staels et al., 1998a; Gervois et 
al., 2001; Jonkers et al., 2002; Kleeman et al., 2003). Several APR markers such as 
fibrinogen, CRP, SAA, α2-macroglobulin and plasminogen are lowered after 
fenofibrate treatment in humans, whereas levels of albumin, which is a negative APR 
protein, is raised. 
 Interestingly, IL-6 effects on acute phase gene expression are fully suppressed 
in fenofibrate-treated wild type, but not in PPARα deficient mice (Gervois et al., 
2004). The global effect of chronic PPARα activation on the expression of positive 
and negative acute phase genes suggests the existence of an upstream suppression of 
IL-6 pathway.  IL-6 induces acute phase genes via a receptor system, consisting of the 
IL-6R (gp80) and gp130 proteins, which initiate a signaling cascade leading to 
downstream activation of transcription factors, such as C/EBP and STAT. In 
fenofibrate-treated wild-type mice, PPARα down-regulates expression levels of the 
IL-6R (gp80) and the signal transducer gp130 and reduces levels of phosphorylated 
STAT3 (Gervois et al., 2004), thus contributing to the global suppression of IL-6 
induced acute phase gene transcription by PPARα agonists. Moreover, PPARα was 
also regulated by the expression of several key APP induced by IL-6. Even though the 
expression of PPARα has been found to be down-regulated by cytokines and LPS 
during physiological and pathophysiological changes (Beier et al., 1997; Beigneux, et 
al., 2000; Fang et al., 2004; Feingold et al., 2004), limited research has been carried 
out to look into the action of IL-6 on PPARα gene expression.   
 Recently, Chew et al. (2007) reported the molecular mechanisms by which 
PPARα was regulated by IL-6 in human HepG2 cells. IL-6-mediated inhibition of 
 24 
PPARα gene expression was discovered to involve the activation of C/EBP isoforms. 
Interestingly, LPS and cytokine administration also decreases both protein and mRNA 
levels of PPARα in the liver of hamster and mice (Beigneux et al., 2000; Beigneux et 
al., 2002; Kim et al., 2003). In addition, LPS administration significantly reduced the 
expression of NHR such as PPARγ, PPARβ/δ, RXR and FXR (Beigneux et al., 2000; 
Beigneux et al., 2002; Kim et al., 2003; Khovidhunkit et al., 2004). Therefore, these 
published reports strongly indicate the implication of roles played by PPARα in 
inflammation, lipid metabolism and atherosclerosis, which are linked to APR in the 
mechanisms of coordinating the regulation of multiple genes induced by cytokines. 
 The action of PPARα on acute phase gene expression is not restricted to the 
IL-6 signalling pathway. As shown in the case of CRP, chronic activation of PPARα 
also prevents IL-1 stimulation of acute phase genes such as SAA in vivo (Zambon et 
al., 2006). PPARα activation thus, impairs cytokine-signalling pathways in the liver, 
acting at different levels, resulting in a potent modulation of APR reaction. PPARα is 
known to have the ability to sense intracellular lipid levels and orchestrated changes 
in lipid metabolism, therefore, the receptor has been recognised as liposensor (Chawla 
et al., 2001; Khovidhunkit et al., 2004).  
 Alterations observed in the activity of NHR liposensors are likely to play a 
pivotal role in the coordinated regulation of fatty acid, cholesterol metabolism and 
reverse cholesterol transport that occurs during the APR. The fatty acid binding 
protein (FABP) is well known to be down-regulated in response to infection or 
inflammation and is also well known target for PPARα (Memon et al., 1999; Landrier 
et al., 2004; Bornar et al., 2006). 
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1.8 Cytokines and IL-6 
 Cytokines are small hormone-like proteins that play a pivotal role in the 
development and pathology of human disease, including diseases of the immune 
response. Since their discovery and cloning, it has become abundantly clear that 
cytokines play critical roles in regulating immune and inflammatory cells (Heinrich et 
al., 1991).They generally act over short distances and short time spans and at very 
low concentrations. The most remarkable characteristics of cytokines is that they can 
act on cells that secrete them (autocrine action), on nearby cells (paracrine action), or 
in some instances on distant cells (endocrine action). It is common for different cell 
types to secrete the same cytokine or a single cytokine to act on several different cell 
types (pletotropy). Cytokines are redundant in their activity, which means that 
different cytokines can also stimulate a similar function in cells. Cytokines are often 
produced in cascade, as one cytokine stimulates its target cells to make additional 
cytokines. Cytokines can interact synergistically or antagonistically with each other 
(Heinrich et al., 2003). 
 Cytokines have been classified (1) on the basis of their biological responses, 
(2) according to the receptors used or (3) according to their dimensional structures 
(Heinrich et al., 1998). Based on the classification of their biological responses, three 
main groups of cytokines can be distinguished: (1) cytokines that primarily act as 
positive or negative growth factors for a variety of cells (IL-2, IL-3, IL-4, IL-7, IL-10, 
IL-11, IL-12 and granulocyte-macrophage colony stimulating factor), (2) cytokines 
with pro-inflammatory properties (TNFα/β, IL-1α/β, IL-6, IFN-α/γ, IL-8, and 
macrophage inhibitory protein-1), and (3) factors with anti-inflammatory activity (IL-
1 receptor antagonists, TNF-α binding protein and IL-1 binding protein). 
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 Hence, IL-6 being a pro-inflammatory cytokine, plays an important role as 
mediator involved in the regulation of the acute-phase response to injury and 
infection. Besides their functions in inflammation and the immune response, IL-6 also 
plays a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal 
development and fertility (Gervois et al., 2004; Chang et al., 2005; Song and Kellum, 
2005). 
 IL-6 was first discovered and named interferon-β2 (IFN-β2) in 1980 by 
Weissenbach and colleagues (Weissenbach et al., 1980) during an effort to clone and 
characterize the interferon-β gene in human fibroblasts. The cytokine was 
subsequently named B-cell stimulatory factor-2 (Hirano et al., 1985), B cell 
differentiation factor, T cell-replacing factor, 26-kDa protein (Haegeman et al., 1986), 
hybridoma growth factor (Brakenhoff et al., 1987; Van Snick et al., 1986), interleukin 
hybridoma plasmacytoma factor 1, plasmacytoma growth factor (Nordan et al., 1987), 
hepatocyte-stimulating factor (Gauldie et al., 1987), macrophage granulocyte-
inducing factor 2, cytotoxic T cell differentiation factor (Takai et al., 1988) and 
thrombopoietein due to its biological functions. In 1989, when these variously named 
proteins were found to be identical on the basis of their amino acid and/or nucleotide 
sequences, the name IL-6 was settled upon (Akira and Kishimoto, 1992; Song and 
Kellum, 2005).  
 IL-6 is a member of a cytokine family that consists of leukemia inhibitory 
factor (LIF), ciliary neurotropic factor (CNTF), IL-11, oncostatin M (OSM) and 
cardiotrophin 1 (CT-1). Members of this cytokine family contain four antiparallel α-
helices termed A, B, C and D that are connected by two long, and one short, loops 
(Figure 1.6) (Heinrich et al., 2003; Song and Kellum, 2005). Although each of the IL-
6 type cytokine is recognized by a specific receptor complex, they all share a common  
